Gary Kobinger

Our main interest is to develop and test novel vaccine platforms for different applications including the protection against emerging pathogens. The new vaccine platforms that are being generated and evaluated are mainly derived from viruses, pathogenic as well as non-pathogenic (e.g. HIV, Adenovirus, AAV). Our efforts focus on modifying existing viruses at the molecular level and/or creating hybrid viruses for safe and efficient stimulation of a protective immunity against different pathogens including containment Level (CL) 4 viruses. An ongoing objective is to evaluate each vaccine strategy with the intent of identifying immune mechanisms and requirements correlating with immune protection. These findings should facilitate future selection and development of safer and more efficient vaccine strategies